Genotoxic Effects of Tributyltin and Triphenyltin Isothiocyanates, Cognate RXR Ligands: Comparison in Human Breast Carcinoma MCF 7 and MDA-MB-231 Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
09 Mar 2019
Historique:
received: 28 01 2019
revised: 27 02 2019
accepted: 06 03 2019
entrez: 13 3 2019
pubmed: 13 3 2019
medline: 25 6 2019
Statut: epublish

Résumé

The cytotoxicity of two recently synthesized triorganotin isothiocyanate derivatives, nuclear retinoid X receptor ligands, was tested and compared in estrogen-receptor-positive MCF 7 and -negative MDA-MB-231 human breast carcinoma cell lines. A 48 h MTT assay indicated that tributyltin isothiocyanate (TBT-ITC) is more cytotoxic than triphenyltin isothiocyanate (TPT-ITC) in MCF 7 cells, and the same trend was observed in the MDA-MB-231 cell line. A comet assay revealed the presence of both crosslinks and increasing DNA damage levels after the 17 h treatment with both derivatives. Differences in cytotoxicity of TBT-ITC and TPT-ITC detected by FDA staining correspond to the MTT data, communicating more pronounced effects in MCF 7 than in the MDA-MB-231 cell line. Both derivatives were found to cause apoptosis, as shown by the mitochondrial membrane potential (MMP) depolarization and caspase-3/7 activation. The onset of caspase activation correlated with MMP dissipation and the total cytotoxicity more than with the amount of active caspases. In conclusion, our data suggest that the DNA damage induced by TBT-ITC and TPT-ITC treatment could underlie their cytotoxicity in the cell lines studied.

Identifiants

pubmed: 30857277
pii: ijms20051198
doi: 10.3390/ijms20051198
pmc: PMC6429456
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Isothiocyanates 0
Organotin Compounds 0
Retinoid X Receptors 0
Trialkyltin Compounds 0
tributyltin 4XDX163P3D
triphenyltin 95T92AGN0V

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-15-0372
Organisme : Scientific Grant Agency of the Ministry of Education of Slovak Republic and the Academy of Sciences
ID : 2/0084/16, 2/0092/16 and 1/0136/18
Organisme : IGA UVPS Brno
ID : 320/2018/FaF
Organisme : Research & Development Operational Programme funded by the ERDF
ID : TRANSMED, ITMS: 26240120008 and ITMS: 26240220071 and TRANSMED 2, ITMS: 26240120030

Références

Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
Cytometry. 1999 Nov 1;37(3):191-6
pubmed: 10520199
Anticancer Drugs. 2002 Jul;13(6):599-604
pubmed: 12172505
Mol Endocrinol. 2005 Oct;19(10):2502-16
pubmed: 15941851
Endocrinology. 2006 Jun;147(6 Suppl):S50-5
pubmed: 16690801
Br J Cancer. 2006 Nov 20;95(10):1348-53
pubmed: 17060935
J Toxicol Sci. 2008 Aug;33(3):269-76
pubmed: 18670157
EMBO Rep. 2009 Apr;10(4):367-73
pubmed: 19270714
Drug Discov Today. 2009 May;14(9-10):500-8
pubmed: 19429510
Neoplasma. 2009;56(6):548-56
pubmed: 19728765
BMC Cancer. 2009 Oct 10;9:359
pubmed: 19818145
Neoplasma. 2010;57(5):473-81
pubmed: 20568902
Aquat Toxicol. 2012 Oct 15;122-123:106-12
pubmed: 22750117
Eur J Pharm Sci. 2012 Sep 29;47(2):490-6
pubmed: 22841513
J Agric Food Chem. 2013 May 1;61(17):4195-203
pubmed: 23534342
Mutagenesis. 2013 Jul;28(4):427-32
pubmed: 23630247
Mol Nutr Food Res. 2014 Aug;58(8):1685-707
pubmed: 24510468
Toxicol Lett. 2014 Nov 4;230(3):479-86
pubmed: 25159039
Toxicol Lett. 2015 Apr 2;234(1):50-8
pubmed: 25683035
Comp Biochem Physiol C Toxicol Pharmacol. 2015 Oct-Nov;176-177:79-86
pubmed: 26256121
Tumour Biol. 2016 May;37(5):6701-8
pubmed: 26662104
Toxicol Lett. 2016 Jul 8;254:32-6
pubmed: 27153798
Endocr Regul. 2016 Jul;50(3):154-64
pubmed: 27560799
Toxicol Lett. 2017 Sep 5;279:16-21
pubmed: 28709983
Gen Physiol Biophys. 2017 Oct;36(4):481-484
pubmed: 28836501
Eur J Nutr. 2018 Oct;57(7):2547-2569
pubmed: 28864908
Gen Physiol Biophys. 2018 Jan;37(1):93-99
pubmed: 29424354
Int J Mol Sci. 2018 Mar 23;19(4):null
pubmed: 29570671
Molecules. 2018 May 01;23(5):null
pubmed: 29723984
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15
pubmed: 8893876
Mutat Res. 1997 May 1;383(3):243-52
pubmed: 9164485

Auteurs

Luba Hunakova (L)

Cancer Research Institute, BMC, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic. Luba.Hunakova@savba.sk.

Eva Horvathova (E)

Cancer Research Institute, BMC, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic. Eva.Horvathova@savba.sk.

Karolina Majerova (K)

Cancer Research Institute, BMC, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic. Karolina.Majerova@savba.sk.

Pavel Bobal (P)

Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1946/1, 612 42 Brno, Czech Republic. bobalp@vfu.cz.

Jan Otevrel (J)

Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1946/1, 612 42 Brno, Czech Republic. otevrelj@vfu.cz.

Julius Brtko (J)

Institute of Experimental Endocrinology, BMC, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic. Julius.Brtko@savba.sk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH